FDA Clearance Tracker · P210037
Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management
Last checked: Nov 20, 2026Latest source record: Mar 31, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Mar 31, 2023
Approved
Time to decision
484 days
Received Dec 2, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P210037
- Device name
- Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management
- Applicant
- Biotronik Nro, Inc.
- Applicant location
- Lake Oswego, OR
- Received
- Dec 2, 2021
- Decided
- Mar 31, 2023
- Decision
- Approved
- Supplements
- 14 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Prospera Spinal Cord Stimulation (SCS) System, Resilience Percutaneous Lead, HomeStream Remote Management. The Indications for Use (IFU) of the device is as follows:The Prospera spinal cord stimulation (SCS) system is indicated as an aid in the management of chronic, intractable pain in the trunk and/or limbs, which may include unilateral or bilateral pain, resulting from any of the following: 1) Failed Back Syndrome (FBS) or low back syndrome or failed back; 2) Radicular pain syndrome or radiculopathies resulting in pain secondary to FBS or; 3) herniated disk; 4) Postlaminectomy pain; 5) Multiple back operations; 6) Unsuccessful disk surgery; 7) Degenerative Disk Disease (DDD)/herniated disk pain refractory to conservative and; 8) surgical interventions; 9) Peripheral causalgia;10) Epidural fibrosis;11) Arachnoiditis or lumbar adhesive arachnoiditis; and12) Complex Regional Pain Syndrome (CRPS), Reflex Sympathetic Dystrophy (RSD), or causalgiai.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LGW. The earliest in FDA's data is P800040, decided Apr 14, 1981.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Biotronik Nro, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.